STAT reported that venture firm Forbion has completed a fundraising round totaling $2.6 billion, described as the firm’s largest fundraise to date. The source provides this headline-level fact but does not include further details in the provided excerpt: it does not list participating limited partners or anchor investors, the fund’s formal name or vintage, sector focus, target allocation across stages, or explicit plans for deploying the capital. Those specifics were not reported in the portion of the article available in the source.
The article’s subtitle mentions that promising therapies for Duchenne muscular dystrophy will challenge regulators and test FDA flexibility. The source excerpt does not supply the names of the therapies, sponsoring companies, trial data, regulatory pathways under consideration, or timelines. Therefore, while the subtitle signals an important regulatory and clinical theme, the underlying details were not reported in the source material provided.
STAT reported that Cerevance announced positive Phase 3 trial results for its experimental oral pill, solengepras, noting that the therapy reduced patients’ daily off-time and provided other motor and nonmotor symptom benefits. The company plans to talk with regulators about a potential approval. The source attributes the Phase 3 outcome to Cerevance and links to the company’s announcement, but the excerpt does not present numerical efficacy data, safety findings, trial size, primary and secondary endpoint specifics, or the planned regulatory submission pathway; those detailed data were not reported in the available excerpt.
The source notes that the 2026 Nobel Prize in Chemistry was awarded to Henri B. Kagan and Kenso Soai for discoveries enabling manipulation of “mirror image” molecules. STAT highlights the prize’s potential implications for more precise and safer drug manufacturing. The article provides this high-level context but does not expand into technical detail about which drug classes or manufacturing processes will be most affected; those specifics were not reported in the excerpt.
STAT reports that Caribou Biosciences, co-founded by Jennifer Doudna, is shutting down after failing to raise sufficient funds to support a late-stage clinical trial of its off‑the‑shelf CAR‑T therapy for lymphoma. The source links the shutdown directly to an inability to secure the capital necessary for that late‑stage program. The provided excerpt does not include further details such as timelines for winding down, status of employees, the disposition of assets or intellectual property, or statements from company leadership; those items were not reported in the excerpt.
STAT announced its 2026 Wunderkinds, recognizing early-career researchers doing innovative work in health and medicine. The article mentions an NIH researcher profiled for work dissecting how GLP‑1 drugs act in the brain, and it links to a set of profiles. Beyond that reference, the excerpt does not enumerate the full Wunderkinds list in the body or summarize additional individual profiles.
This roundup is authored by Elaine Chen, STAT’s National Biotech Reporter, and is dated Oct. 7, 2026. The source includes links and prompts to subscribe to STAT+; several items in the article and related stories are behind a STAT+ paywall. The provided excerpt contains navigational and promotional material from STAT’s site, including newsletter signups and links to related reporting. Where the excerpt omitted substantive data or follow-up information for the items above, the text explicitly notes that those details were not reported in the source portion supplied.
The source delivers several concise biotech developments: Forbion’s headline $2.6 billion fundraise, Cerevance’s positive Phase 3 announcement for solengepras in Parkinson’s disease, the awarding of the 2026 Nobel Prize in Chemistry with relevance to drug manufacturing, and the shutdown of Caribou Biosciences due to funding shortfalls for a late‑stage CAR‑T program. Multiple items referenced in the article—most notably details about Forbion’s fund, Duchenne therapies, and full trial data for solengepras—were not reported in the provided excerpt. Readers seeking the granular financial, clinical, or regulatory data cited by the piece should consult the full STAT article or the companies’ primary disclosures, where available.